PD-1 Combined With Bevacizumab and PCSK-9 Inhibitor in Patients With Advanced NSCLC Who Have Progressed After Anti- PD- 1/L1 Therapy

Clinical trial NCT07014215 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07014215
Sponsor: Anhui Provincial Cancer Hospital
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

NSCLC (Advanced Non-small Cell Lung Cancer)Resistance to Immunotherapy

Start date: 2025-06-01
Primary completion: 2027-05-01
Enrollment: 52

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.